Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Cancer remains a leading cause of death worldwide. Despite many signs of progress, currently available cancer treatments often do not provide desired outcomes for too many cancers. Therefore, newer and more effective therapeutic approaches are needed. Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively targets and kills cancer cells while sparing normal ones. In the past several decades, many different OV candidates have been developed and tested in both laboratory settings as well as in cancer patient clinical trials. Many approaches have been taken to overcome the limitations of OVs, including engineering OVs to selectively activate anti-tumor immune responses. However, newer approaches like the combination of OVs with current immunotherapies to convert “immune-cold” tumors to “immune-hot” will almost certainly improve the potency of OVs. Here, we discuss strategies that are explored to further improve oncolytic virotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“After secretion, DAMP molecules bind to their receptors CD91 (CRT), P2RX7 (ATP), and TLR4 (HMGB1) on dendritic cells (DCs), which subsequently mature, process antigens, and then educate/activate T cells to enhance antitumor responses [49,50].”
BackgroundInhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · cited 1×
“Similarly, oncolytic NDV also promoted PD-L1 production in the tumor bed in response to the virus stimulated type I IFN signaling, resulting in an immunosuppressive TME even in distant tumors [68,69].”
BackgroundThe cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293 · cited 1×
“IFN gene expression, the release of chemokines CXCL9 and CXCL10, and ultimately the recruitment of T cells [51,52].”
BackgroundInhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z., Roychoudhuri, R., Palmer, D. C., Muranski, P., Karoly, E. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69589 · Cited by 952 · cited 1×
“Studies have shown that inhibition of tumor cell glycolytic metabolism enhanced antitumor immune responses and the function of chemotherapy drugs [29,30].”
BackgroundZamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704
Complexes of poliovirus serotypes with their common cellular receptor, CD155
He, Y., Mueller, S., Chipman, P. R., Bator, C. M., Peng, X., Bowman, V. D., Mukhopadhyay, S., Wimmer, E., Kuhn, R. J., & Rossmann, M. G. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4827-4835.2003 · Cited by 98
Metadata
- Authors
- Rahman, M. M., & McFadden, G.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-10-29
- Volume
- 13
- Issue
- 21
- Pages
- 5452
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3210054708
- Cited by
- 165
- References
- 9
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. https://app.cochat.ai/papers/10.3390/cancers13215452
- The paper
- Rahman, M. M., & McFadden, G. (2021). Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers. https://doi.org/10.3390/cancers13215452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.